Latest papers

First drug for rare cancer.

Manual and automated AgNOR count in differentiating reactive mesothelial from metastatic malignant cells in serous effusions.

Peritoneal carcinomatosis: role of (18)F-FDG PET.

[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib]

Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells.

Echocardiographic diagnosis of right atrial mass: diagnostic pitfalls.

Extragastrointestinal stromal tumor of the greater omentum: case report and review of the literature.

Mesothelial cells: their structure, function and role in serosal repair.

Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.

Alterations of the p16(INK4) locus in human malignant mesothelial tumors.

Cytotoxic effects of macrophages and asbestos on transformed rat mesothelial cells.

Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.

Angiogenesis is an independent prognostic factor in malignant mesothelioma.

Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.

SV40 and the pathogenesis of mesothelioma.

Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas.

SV40 and cell cycle perturbations in malignant mesothelioma.

Increased fatty acid synthase is a therapeutic target in mesothelioma.

Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.

Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway.